vs
Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $164.7M, roughly 1.6× PTC THERAPEUTICS, INC.). WESBANCO INC runs the higher net margin — 34.5% vs -82.0%, a 116.4% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs -11.5%).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
PTCT vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $164.7M | $257.2M |
| Net Profit | $-135.0M | $88.6M |
| Gross Margin | — | — |
| Operating Margin | -43.3% | — |
| Net Margin | -82.0% | 34.5% |
| Revenue YoY | -22.7% | — |
| Net Profit YoY | -104.8% | 54.4% |
| EPS (diluted) | $-1.63 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $164.7M | $265.6M | ||
| Q3 25 | $211.0M | $261.6M | ||
| Q2 25 | $178.9M | $260.7M | ||
| Q1 25 | $1.2B | $193.2M | ||
| Q4 24 | $213.2M | $162.9M | ||
| Q3 24 | $196.8M | $150.8M | ||
| Q2 24 | $186.7M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $-135.0M | $91.1M | ||
| Q3 25 | $15.9M | $83.6M | ||
| Q2 25 | $-64.8M | $57.4M | ||
| Q1 25 | $866.6M | $-9.0M | ||
| Q4 24 | $-65.9M | $49.6M | ||
| Q3 24 | $-106.7M | $37.3M | ||
| Q2 24 | $-99.2M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | -43.3% | 43.2% | ||
| Q3 25 | 1.4% | 39.5% | ||
| Q2 25 | -19.5% | 27.2% | ||
| Q1 25 | 82.5% | -5.0% | ||
| Q4 24 | -76.2% | 38.0% | ||
| Q3 24 | -27.7% | 29.7% | ||
| Q2 24 | -21.5% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | -82.0% | 34.3% | ||
| Q3 25 | 7.5% | 31.9% | ||
| Q2 25 | -36.3% | 22.0% | ||
| Q1 25 | 73.7% | -4.7% | ||
| Q4 24 | -30.9% | 30.5% | ||
| Q3 24 | -54.2% | 24.7% | ||
| Q2 24 | -53.1% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $-1.63 | $0.97 | ||
| Q3 25 | $0.20 | $0.84 | ||
| Q2 25 | $-0.83 | $0.57 | ||
| Q1 25 | $10.04 | $-0.15 | ||
| Q4 24 | $-0.85 | $0.72 | ||
| Q3 24 | $-1.39 | $0.54 | ||
| Q2 24 | $-1.29 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-205.3M | $4.1B |
| Total Assets | $2.9B | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.9B | $956.1M | ||
| Q3 25 | $1.7B | $1.0B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $2.0B | $1.1B | ||
| Q4 24 | $1.1B | $568.1M | ||
| Q3 24 | $1.0B | $620.9M | ||
| Q2 24 | $1.1B | $486.8M |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $-205.3M | $4.0B | ||
| Q3 25 | $-155.8M | $4.1B | ||
| Q2 25 | $-206.5M | $3.8B | ||
| Q1 25 | $-185.8M | $3.8B | ||
| Q4 24 | $-1.1B | $2.8B | ||
| Q3 24 | $-1.1B | $2.8B | ||
| Q2 24 | $-980.2M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $2.9B | $27.7B | ||
| Q3 25 | $2.6B | $27.5B | ||
| Q2 25 | $2.6B | $27.6B | ||
| Q1 25 | $2.7B | $27.4B | ||
| Q4 24 | $1.7B | $18.7B | ||
| Q3 24 | $1.8B | $18.5B | ||
| Q2 24 | $1.9B | $18.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.3M | — |
| Free Cash FlowOCF − Capex | $-36.6M | — |
| FCF MarginFCF / Revenue | -22.3% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $702.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-34.3M | $290.4M | ||
| Q3 25 | $-66.3M | $116.9M | ||
| Q2 25 | $-58.3M | $105.0M | ||
| Q1 25 | $870.1M | $-26.4M | ||
| Q4 24 | $-30.0M | $211.0M | ||
| Q3 24 | $-77.0M | $60.7M | ||
| Q2 24 | $-71.5M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-36.6M | $280.0M | ||
| Q3 25 | $-69.7M | $114.9M | ||
| Q2 25 | $-59.6M | $98.3M | ||
| Q1 25 | $868.4M | $-30.7M | ||
| Q4 24 | $-33.8M | $200.7M | ||
| Q3 24 | $-77.5M | $56.9M | ||
| Q2 24 | $-78.8M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | -22.3% | 105.4% | ||
| Q3 25 | -33.1% | 43.9% | ||
| Q2 25 | -33.3% | 37.7% | ||
| Q1 25 | 73.8% | -15.9% | ||
| Q4 24 | -15.8% | 123.2% | ||
| Q3 24 | -39.4% | 37.7% | ||
| Q2 24 | -42.2% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 3.9% | ||
| Q3 25 | 1.6% | 0.8% | ||
| Q2 25 | 0.7% | 2.6% | ||
| Q1 25 | 0.1% | 2.2% | ||
| Q4 24 | 1.8% | 6.3% | ||
| Q3 24 | 0.3% | 2.5% | ||
| Q2 24 | 4.0% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | -4.17× | 1.40× | ||
| Q2 25 | — | 1.83× | ||
| Q1 25 | 1.00× | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PTCT
Segment breakdown not available.
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
